|
|
Profile
|
Delegates :
Hayato Watanabe |
|
Incorporated :
March 1 , 2022 |
Paid in Capital :
53 Million yen |
Employees :
8 人 |
Address :
Nagoya University Incubation Facility Furo-cho 1, Chikusa-ku, Nagoya AICHI
〒464-0814
|
TEL/FAX :
/ |
URL：
https://craftonbio.com/ |
Attachment :
|
Mission/Background :
Crafton aims to become a globally competitive mRNA company by leveraging innovative mRNA technologies that drive the emergence of new therapeutic modalities. Through agile management decisions and focused research and development, we seek to continuously generate breakthrough technologies with the potential to shape the future of medicine.
Our mission is to realize innovative mRNA drug discovery and development through our proprietary platform technologies, and to deliver safer medicines to children who will shape the future, to patients suffering from intractable diseases, and to people around the world who can benefit from preventive therapies.
|
|
Technology & Business
|
Crafton Biotechnology is a mRNA biotechnology company developing novel therapeutics through proprietary RNA production, delivery, and synthesis technologies.
The company is focused on addressing key bottlenecks in mRNA medicine, including impurity-driven innate immune activation, manufacturing complexity, delivery limitations, and the need for improved therapeutic performance in high-value clinical applications.
By combining high-purity mRNA production through PureCap (R), application-specific delivery strategies, and advanced RNA synthesis technologies, Crafton aims to enable safer, more scalable, and more clinically translatable mRNA medicines. Crafton is also developing LNP-free intradermal delivery using needle-free jet injectors, as well as mRNA medicines that induce therapeutic antibodies in vivo.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
PureCap (R) mRNA Manufacturing Platform
|
Service/Marketing
|
Proprietary platform for production of highly purified capped mRNA
|
Expand pharmaceutical partnerships
|
Infectious Disease mRNA Vaccines
|
Preclinical
|
Next-generation mRNA vaccines using proprietary RNA technologies
|
Initiate Phase 1 clinical trial
|
Oncology mRNA Therapeutics
|
Discovery
|
mRNA-based therapies for cancer treatment and immunotherapy
|
Expand development pipeline
|
Antibody-Inducing mRNA Therapeutics
|
Discovery
|
mRNA medicines that induce therapeutic antibodies in vivo
|
Validate therapeutic candidates
|
Research Collaboration & Licensing
|
Service/Marketing
|
Collaborative research and licensing of proprietary RNA technologies
|
Increase industry alliances
|
|
Highlights
|
Crafton has expanded its mRNA platform through multiple strategic collaborations. The company signed an agreement with FUJIFILM Wako Pure Chemical for manufacturing and commercialization of novel phosphoramidite reagents enabling high-purity mRNA synthesis. Crafton also initiated collaborative research with FunPep combining antibody-inducing peptide technology with its proprietary mRNA platform and was selected for the Aichi Deeptech Launchpad acceleration program.
|
|
Hot news
|
Crafton continues to strengthen commercialization of its proprietary mRNA platform through strategic partnerships and collaborative research activities. Recent initiatives include exhibiting at JHVS 2026 alongside BioJapan 2026, a pitch at SHIC FAST TRACK 2026, expansion of industry collaborations, and business development activities aimed at accelerating the practical application of high-purity mRNA technologies and next-generation RNA medicines.
|
|
Alliance strategy
|
Crafton seeks partnerships with pharmaceutical companies, biotechnology firms, academic institutions, and research organizations. Areas of interest include joint research, co-development, licensing, and technology alliances involving mRNA therapeutics, vaccine development, RNA synthesis, manufacturing technologies, and delivery systems. The company welcomes opportunities to apply its PureCap (R); platform to novel therapeutic programs and collaborative innovation projects.
|
|
|